Corporate Banner
Satellite Banner
Medicinal Chemistry
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

ElexoPharm GmbH Receives ETB Grant

Published: Thursday, October 18, 2012
Last Updated: Thursday, October 18, 2012
Bookmark and Share
EuroTransBio grant of €1.5 million for tumor vessel targeting program ('Small Mol Act').

Recently, a EuroTransBio grant of €1.5 million has been awarded to a transnational consortium including ElexoPharm GmbH by the European Collaborative ETB program.

The project is a collaboration of ElexoPharm GmbH with SomantiX BV (Bilthoven, The Netherlands), VU University Medical Center (Amsterdam, The Netherlands), Saarland University (Saarbrücken, Germany) and PharmBioTec GmbH (Saarbrücken, Germany).

This subsidy is awarded for a period of three years and will allow the development of low molecular weight inhibitors of angiogenesis in colorectal cancer.

At ElexoPharm, lead finding and lead optimization based on molecular modelling, design and synthesis of biological active compounds, will be performed.

"ElexoPharm is very proud to have received this prestigious transnational grant to develop medicines to treat this disease of high medical need. It is a further recognition of the excellent drug discovery capabilities of our growing company", states Axel Koch, Managing Director of ElexoPharm.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,400+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

ElexoPharm Appoints Dr. Chris J. van Koppen as Head of Research
Dr. Koppen will lead the preclinical drug discovery projects of ElexoPharm and will build further alliances with larger pharmaceutical companies.
Monday, April 16, 2012
ElexoPharm Appoints Dr. Chris J. van Koppen as Head of Research
Dr. Koppen will lead ElexoPharm’s preclinical drug discovery projects.
Monday, April 16, 2012
Scientific News
Experimental Drug Cancels Effect from Key Intellectual Disability Gene
A University of Wisconsin—Madison researcher who studies the most common genetic intellectual disability has used an experimental drug to reverse — in mice — damage from the mutation that causes the syndrome.
Doubling Down on Dengue
HMS researchers have discovered two ways a compound blocks dengue virus.
Reprogramming Scorpion Venom
‘Twist of nature’ neutralizes toxin.
Tailoring a Suit for Tumor-Penetrating Cancer Meds
For more than a decade, biomedical researchers have been looking for better ways to deliver cancer-killing medication directly to tumors in the body.
Resurrecting an Abandoned Drug
Previously discarded drug shows promise in helping human cells in a lab dish fight off two different viruses.
Safer, Cheaper, Greener and More Efficient System for Organic Synthesis
The new medium not only supports organic synthesis it also produces considerably higher yields of product than pure organic solvents.
Fighting Prostate Cancer
Identifying the most promising compounds which can be used as medications for prostate cancer.
Collaboration to Develop Cancer Therapeutics
Major license agreement with Merck, enabled by Blavatnik Biomedical Accelerator, aims to develop therapy for most common form of acute leukemia.
Faster UVA Molecular Analysis Technology
There are people in the world – chemical engineers, astronomers, national defense scientists investigating an explosion – who need to know just what something is made of, down to the molecular level.
Scientists Synthesize Anti-Cancer Agent
A team led by Rice University synthetic organic chemist K.C. Nicolaou has developed a new process for the synthesis of a series of potent anti-cancer agents originally found in bacteria.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,400+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!